Influence of cannabidiol on metabolic processes in the development of psoriasis

---

Adam Aleksander Wronski

Medical University of Bialystok, Poland

: J Clin Exp Dermatol Res

Abstract

---

Psoriasis is one of the most common dermatoses that affect not only the skin, but also other organs. Symptoms of this systemic disease may appear in very young people, including children, as well as in adults, regardless of gender. In Poland, psoriasis patients account for about 2-4% of the total population, while globally it is about 1-3%. Psoriasis, along with atopic dermatitis, is one of the most common dermatological conditions. The problem of this dermatosis is also important because these patients are at increased risk of developing other serious chronic diseases such as, such as psoriatic arthritis, metabolic syndrome, cardiovascular disorders, depression, non-alcoholic fatty liver disease, Crohn's disease and lymphomas. Despite significant advances in treatment, especially for patients with moderate-to-severe psoriasis, there is still a great need for new treatments, especially for patients for whom the systemic psoriasis therapy cannot be applied. Therefore, due to the observed disturbances in phospholipid metabolism in the development of psoriasis, I joined the research aimed at determining the influence of one of the non-psychoactive phytocannabinoids, Cannabidiol (CBD), on metabolic processes in the development of this dermatosis. The subject of the analysis is to present the experimental data of recent years on the influence of CBD on the pathogenesis of psoriasis and the possibility of using CBD in the pharmacotherapy of psoriasis. Analyzing this problem from as dermatologist, I can underline that CBD is safe for topical application and has no significant side effects, as demonstrated by in vitro studies using clinical material (blood, skin cells) and confirmed by in vivo animal studies. Nevertheless, its use in dermatology in the treatment of psoriatic dermatosis in humans requires clinical trials that are yet to be conducted. However, the current state of knowledge indicates the real possibilities of using this compound in clinical practice.

Biography

---

Adam Wronski is a specialist dermatologist with more than 25 years of experience. He practices at a Clinical Dermatology Centre DERMAL in Bialystok (Poland). He has conducted numerous clinical trials of dermatological treatments, including in the field of pharmacotherapy of psoriasis. He is affiliated with the Medical University of Bialystok, where he teaches dermatology and carries out scientific and research work on new methodologies for diagnosing and treating psoriasis.